Articles

Geneuity adopts Thermo’s next- gen tech and Oncomine assay

Company is expanding early access to Thermo Fisher technology for upcoming services to pharma customer base
Written byJeffrey Bouley
| 3 min read

CARLSBAD, Calif.—Geneuity, which boasts skills in the integration of molecular diagnostics and pathology testing for contract research organizations (CROs), pharmaceutical companies and medical device companies, announced this summer that it is expanding early access to Thermo Fisher Scientific’s targeted, next-generation sequencing technology and Oncomine Focus Assay for services that it plans to offer to its broad pharmaceutical customer base.

“The biomarkers included in the Oncomine Focus Assay were selected using the Oncomine Knowledgebase and confirmed with industry-leading pharmaceutical companies to help enable a more unified approach to companion diagnostic development,” said Mike Nolan, vice president and general manager of oncology at Thermo Fisher Scientific. “Coupled with the Ion PGM System, the assay offers a powerful and sophisticated solution for drug development research applications.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.